Clinical Trial: Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational

Official Title: Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Brief Summary: This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Detailed Summary: People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes
Sponsor: Johns Hopkins University

Current Primary Outcome: Mean change from baseline in BCVA at 5 and 10 years. [ Time Frame: 10 years ]

Mean change from baseline in BCVA at 5 and 10 years.


Original Primary Outcome: Same as current

Current Secondary Outcome: Mean change from baseline in foveal thickness at 5 and 10 years [ Time Frame: 10 years ]

Mean change from baseline in foveal thickness at 5 and 10 years


Original Secondary Outcome: Same as current

Information By: Johns Hopkins University

Dates:
Date Received: June 10, 2013
Date Started: January 2013
Date Completion: December 2020
Last Updated: June 20, 2016
Last Verified: June 2016